Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Patent
1998-09-10
2000-05-09
Moezie, F. T.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
514 2, 514 21, 514885, 514886, 514914, 514 8, 4241581, 53038825, A61K 3802, A61K 3816, A61K 3855
Patent
active
060604492
DESCRIPTION:
BRIEF SUMMARY
BACKGROUND OF THE INVENTION
1. Field of the Invention
The present invention relates to an agent for suppressing growth of the vascular endothelial and an inhibitor of angiogenesis induced by growth of the vascular endothelial cells which comprises Tissue Factor Pathway Inhibitor (TFPI) as active ingredient. More particularly, the present invention relates to a TFPI-containing preparation for prevention and treatment of angiogenic diseases through effective inhibition of angiogenesis induced by growth of the vascular endothelial cells.
2. Description of the Related
Angiogenesis is growth of new blood vessels, especially capillary vessels. Although angiogenesis is a significant physiological event for developing embryos or growing individuals, it is widely known that angiogenesis mostly detrimentally affects healthy adults and is only favorable to healing of wounds or menstrual cycle. In case of malignant tumors, for example, growth of the vascular endothelial cells or angiogenesis of capillary vessels is essential to development of tumor tissue. It is considered this is because the tumor cells produce and secrete a growth factor necessary for angiogenesis, and as a result, the vascular endothelial cells are stimulated to divide and propagate towards the tumor site. Accordingly, inhibition of angiogenesis can be a means to control growth of malignant tumors.
For treating malignant tumors, surgical enucleation of the tumors has been conducted. However, if any one of tumor cells fails to be removed but remains in the affected part after enucleation of the tumors, relapse of the tumor occurs. Moreover, it is reported that tumor cells appearing in blood flow increase during or after surgical nucleation of tumor tissue where angiogenesis is highly developed, implicating an increased risk of metastasis to other organs [McCulloch, P. et al., The Lancet, 346, p1334 (1995)]. In case of such a surgical enucleation of tumor tissue, the use of an angiogenic inhibitor that can inhibit angiogenesis will permit prevention of relapse at the primary focus and growth of metastasized tumor cells and hence can be a means for treating malignant tumors.
In addition to propagation of malignant tumors, there are known various diseases induced by angiogenesis, including the so-called angiogenic diseases such as diabetic retinopathy, retrolental fibroplasia, neovascular glaucoma, psoriasis, angiofibroma, immune and nonimmune inflammation (including rheumatic arthritis), propagation of capillary vessels in arteriosclerosis plaques, angioma and Kaposi's sarcoma [Folkman, J. et al., Science, 235, p442 (1987)]. One can well expect that inhibition of angiogenesis could treat these diseases.
It has been confirmed that the growth of endothelial cells of blood vessel is much significant in the mechanism of angiogenesis. That is, angiogenesis occurs in the following mechanism: (i) the basement membrane of the existing blood vessels is first degraded by the action of a proteolytic enzyme and then the endothelial cells are released out of the locally destroyed membrane, (ii) the released endothelial cells migrate into the extravascular area where they proliferate through cell division, (iii) after the proliferation, they gradually differentiate into the tube-like structure and a new blood vessel is then formed, and (iv) finally the new blood vessel is combined together to complete angiogenesis [Folkman, J. et al., J.Biol.Chem., 267, p10931 (1992)]. As a promoting factor of angiogenesis, there are known peptidic substances, acidic Fibroblast Growth Factor (aFGF) and basic Fibroblast Growth Factor (bFGF), which induce angiogenesis through acceleration of release and growth of the vascular endothelial cells. Recently, a vascular endothelial growth factor/vascular permeability factor (VEGF/VPF), which is a growth factor specific for the vascular endothelial cells, was found as a new promoting factor of angiogenesis [Ferrara, N. et al., J.Clin.Invest., 84, p1470 (1989)].
There are known several compounds that exhibit inhibition against growth of th
REFERENCES:
patent: 5276015 (1994-01-01), Khouri et al.
patent: 5902582 (1999-05-01), Hung
Hambrough et al "Tissue Factor Pathway Inhibitor (TFPI) is an Inhibitor of ngiogenesis" Proceedings of the American Cancer Association for Cancer Research, vol. 40 : 68 #451, 1999.
Hambrough et al., Control of Tumor Growth in Animals by Infusion of an Angiogenesis Inhibitor, Proc. Natl. Acad. Sci. USA, vol. 77, No. 7, 4331-4335, 1980.
McCulloch, P., et al., "Association Between Tumor Angiogenesis and Tumor Cell Shedding into Effluent Venous Blood During Breast Cancer Surgery," The Lancet 346:1335-1335 (1995).
Folkman, J., et al., "Angiogenic Factors," Science 235:442-447 (1987).
Folkman, J., et al., "Angiogenesis," The Journal of Biological Chemistry 267-.sub.16 10931-10934 (1992).
Connolly, D.T., et al., "Tumor Vascular Permeability Factor Stimulates Endothelial Cell Growth and Angiogenesis," Journal of Clinical Investigation 84:1470-1478 (1989).
Taylor, S. et al., "Protamine is an Inhibitor of Angiogenesis," Nature 297:307-312 (1982).
Bronze, G.J., et al., "Isolation of the Tissue Factor Inhibitor Produced by HepG2 Hepatome Cells," Proc. Natl. Acad. Sci. USA 84:1886-1890 (1987).
Wun, T.-C., et al., "Cloning and Characterization of a cDNA Coding for the L.sub.ip oprotein-associated Coagulation Inhibitor Shows That Is Consists of Three Tandem Kunitz-type Inhibitory Domains," J. Biochem. 263:6001-6004 (1988).
Kamei, S., et al., "Amino Acid Sequence and Inhibitory Activity of Rhesus Monkey Tissue Factor Pathway Inhibitor (TFPI): Comparison with Human TFPI," Journal of Biochemistry 115:708-714 (1994).
Wesselschmidt, R.L., et al., "cDNA Sequence of Rabbit Lipoprotein-associated Coagulation Inhibitor," Nucleic Acids Research 18-21:6440 (1990).
Warn-Cramer, B.J., et al., "cDNA Sequence of Rabbit Tissue Factor Pathway Inhibitor," Nucleic Acids Research 20-13:3548 (1992).
Enjyoji, K., et al., "cDNA Cloning and Expression of Rat Tissue Factor Pathway Inhibitor (TFPI)," Journal of Biochemistry 111:681-687 (1992).
Enjyoji, K., et al., "Effect of Heparin on the Inhibition of Factor Xa by Tissue Factor Pathway Inhibitor: A Segment, Gly212-Phe243, of the Third Kunitz Domain Is a Heparin-Binding Site," Biochemistry 34-17:5725-5735 (1995).
"Medicine Today," 49 (5), p. 927 (1994).
Hamuro Tsutomu
Miyamoto Seiji
Nakahara Yo
Takemoto Sumiyo
Juridical Foundation The Chemo-Sero-Therapeutic Research Institu
Moezie F. T.
LandOfFree
Neovascularization inhibitor containing tissue factor pathway in does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Neovascularization inhibitor containing tissue factor pathway in, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Neovascularization inhibitor containing tissue factor pathway in will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1065119